NDA 050587 · Merck
Primaxin
Cilastatin Sodium, Imipenem · Intravenous
NovelPriority reviewLast checked: Nov 19, 2026Latest source record: Jan 30, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1985
Nov 26, 1985
Approved uses
2
Original approval plus efficacy supplements
Registered trials
65
21 Phase 3, 2 recruiting
FAERS reports
2,371
1,943 serious, 560 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 5, 2024.
PRIMAXIN for intravenous use is a combination of imipenem, a penem antibacterial, and cilastatin, a renal dehydropeptidase inhibitor, indicated for the treatment of the following serious infections caused by designated susceptible bacteria: Lower respiratory tract infections. ( 1.1 ) Urinary tract infections. ( 1.2 ) Intra-abdominal infections. ( 1.3 ) Gynecologic infections. ( 1.4 ) Bacterial septicemia. ( 1.5 ) Bone and joint infections. ( 1.6 ) Skin and skin structure infections. ( 1.7 ) Endocarditis. ( 1.8 ) Limitations of Use: PRIMAXIN is not indicated in patients with meningitis because safety and efficacy have not been established ( 1.9 ). PRIMAXIN is not recommended in pediatric patients with CNS infections because of the risk of seizures ( 1.9 ). PRIMAXIN is not recommended in pediatric patients weighing less than 30 kg with impaired renal function ( 1.9 ). Usage: To reduce the development of drug resistant bacteria and maintain the effectiveness of PRIMAXIN and other antibacterial drugs, PRIMAXIN should be used only to treat infections that are proven or strongly suspected to be caused by bacteria ( 1.10 ). 1.1 Lower Respiratory Tract Infections PRIMAXIN for intravenous use is indicated for the treatment of lower respiratory tract infections caused by susceptible strains of Staphylococcus aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, Escherichia coli , Haemophilus influenzae , Haemophilus parainfluenzae , Klebsiella species, Serratia marcescens. 1.2 Urinary Tract Infections (complicated and uncomplicated) PRIMAXIN is indicated for the treatment of urinary tract infections (complicated and uncomplicated) caused by susceptible strains of Enterococcus faecalis , Staphylococcus aureus (penicillinase-producing isolates),...
Mechanism: PRIMAXIN is a combination of imipenem and cilastatin. Imipenem is a penem antibacterial drug [see Microbiology (12.4) ] . Cilastatin is a renal dehydropeptidase inhibitor that limits the renal metabolism of imipenem.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 8, 1998 Supplement 48 · Efficacy LabelLetter
- Nov 26, 1985 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination · priority review Review
2 products under this application
- PRIMAXIN · CILASTATIN SODIUM EQ 250MG BASE/VIAL; IMIPENEM 250MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · POWDER, INTRAVENOUS · Discontinued
- PRIMAXIN · CILASTATIN SODIUM EQ 500MG BASE/VIAL; IMIPENEM 500MG/VIAL · POWDER, INTRAVENOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Cilastatin" as an intervention, any sponsor and status, largest first.
- A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)Pivotal-lookingCompleted
Spero TherapeuticsIndustry
NCT06059846 · 1,690 participants · Start Dec 21, 2023 · Primary completion Jan 27, 2025
Drug: TBP-PI-HBr; Imipenem-cilastatin and 2 more · For: Urinary Tract Infection; Acute Pyelonephritis
Sites: Miami, Florida; Buenos Aires, Argentina; Córdoba, Argentina · 85 sites in all
- Complicated Skin and Skin Structure InfectionsPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00619710 · 1,000 participants (planned) · Start Feb 2001 · Primary completion Dec 2003
Drug: Meropenem; Imipenem-cilastatin · For: Skin Infection; Abscess; Cellulitis
- Study Comparing Tigecycline to Imipenem/Cilastatin in Complicated Intra-Abdominal Infections in Hospitalized SubjectsPivotal-lookingCompleted
Wyeth is now a wholly owned subsidiary of PfizerPfizer (PFE)
NCT00081744 · 850 participants · Start Nov 2002 · Primary completion Aug 2004
Drug: Tigecycline · For: Gram-Positive Bacterial Infections; Cross Infection
- Evaluation of the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With cUTI Including AP (EudraCT no. 2022-000061-40)Pivotal-lookingStatus unknown
Evopoint Biosciences Inc.Industry
NCT05204368 · 780 participants (planned) · Start Mar 30, 2023 · Primary completion Jun 2025
Drug: Combination of Imipenem/Cilastatin and XNW4107; Meropenem · For: Complicated Urinary Tract Infection Including Acute Pyelonephritis
Sites: Baltimore, Maryland
- Prevention of Nephrotoxin-Induced Acute Kidney Injury Using CilastatinPivotal-lookingRecruiting
Matthew JamesAcademic, hospital or other
NCT06886464 · 698 participants (planned) · Start Jul 16, 2025 · Primary completion Dec 31, 2027
Drug: Cilastatin Sodium; Placebo-Saline · For: Acute Kidney Injury
Sites: Calgary, Canada; Edmonton, Canada
- Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated PyelonephritisPivotal-lookingCompleted
Meiji Seika Pharma Co., Ltd.Industry
NCT05887908 · 614 participants · Start May 23, 2023 · Primary completion Nov 22, 2024
Drug: co-administration of cefepime and nacubactam; co-administration of aztreonam and nacubactam and 1 more · For: Complicated Urinary Tract Infection; Acute Pyelonephritis; cUTI and 1 more
Sites: Pleven, Bulgaria; Rousse, Bulgaria; Silistra, Bulgaria · 61 sites in all
- A Trial of HRS-8427 in the Treatment of Adults With Complicated Urinary Tract Infection, Including Acute PyelonephritisPivotal-lookingCompleted
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT06569056 · 579 participants · Start Sep 25, 2024 · Primary completion Sep 1, 2026
Drug: HRS-8427; Imipenem and Cilastatin Sodium and 2 more · For: Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)
Sites: Shanghai, China
- Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT02493764 · 537 participants · Start Nov 24, 2015 · Primary completion Apr 3, 2019
Drug: Imipenem; Relebactam and 4 more · For: Bacterial Pneumonia
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- product use in unapproved indication221
- convulsion188
- drug ineffective127
- pyrexia122
- pneumonia116
- off label use115
- sepsis103
- death91
- renal failure74
- septic shock74
- multi-organ failure72
- rash72
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 193 |
| 2005 | 202 |
| 2006 | 175 |
| 2007 | 172 |
| 2008 | 180 |
| 2009 | 211 |
| 2010 | 152 |
| 2011 | 155 |
| 2012 | 163 |
| 2013 | 25 |
| 2014 | 27 |
| 2015 | 19 |
| 2016 | 29 |
| 2017 | 44 |
| 2018 | 65 |
| 2019 | 81 |
| 2020 | 56 |
| 2021 | 85 |
| 2022 | 67 |
| 2023 | 99 |
| 2024 | 113 |
| 2025 | 38 |
| 2026 | 20 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
To Be Discontinued · updated Jan 8, 2026
Primaxin, Injection, 500mg (NDC 0006-3516-59). To be discontinued approximately 11/30/2026
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Primaxin (Imipenem/Cilastatin Sodium)
2024 spending
$19K
Beneficiaries
15
38 claims
Per beneficiary
$1,240
$9.65 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $45,132 |
| 2021 | $52,933 |
| 2022 | $41,121 |
| 2023 | $21,562 |
| 2024 | $18,604 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK).
Kaye KS, Shorr AF, Wunderink RG, et al. · Lancet Infect Dis 2023 · Randomized Controlled Trial, Multicenter Study
- The risk of seizures among the carbapenems: a meta-analysis.
Cannon JP, Lee TA, Clark NM, et al. · J Antimicrob Chemother 2014 · Meta-Analysis, Research Support, Non-U.S. Gov't
- A Systematic Review of the Pharmacokinetics and Pharmacodynamics of Novel Beta-Lactams and Beta-Lactam with Beta-Lactamase Inhibitor Combinations for the Treatment of Pneumonia Caused by Carbapenem-Resistant Gram-Negative Bacteria.
Rando E, Novy E, Sangiorgi F, et al. · Int J Antimicrob Agents 2024 · Systematic Review
- Efficacy, safety, and tolerability of antimicrobial agents for complicated intra-abdominal infection: a systematic review and network meta-analysis.
Kong W, Deng T, Li S, et al. · BMC Infect Dis 2023 · Systematic Review, Network Meta-Analysis
- Antibiotics for ventilator-associated pneumonia.
Arthur LE, Kizor RS, Selim AG, et al. · Cochrane Database Syst Rev 2016 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Imipenem-cilastatin sodium (Primaxin).
· Med Lett Drugs Ther 1986 · Clinical Trial
Sponsor: Merck
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.